Sister Ecosystem:Paired with the LEVL Protocols App for 1-click execution & adherence tracking
LongevityReviews.org
Evidence Consensus Engine
Back to All Modalities
Raw MarkdownTrack in LEVL
Executive Evidence Consensussilver • 85/100

Urolithin A triggers PINK1/Parkin-mediated selective autophagy of damaged mitochondria (mitophagy), clearing dysfunctional organelle fragments and stimulating fresh mitochondrial biogenesis.

Knowledge Graph:Vector: CellularMitochondria
Head-to-Head CompareAudit in Stack
Mitochondrial HealthCellularSilver Tier85–94Top 5in Mitochondria of 51Top 10in Endurance of 28Moderate Confidence (Translational)⚖️ Scientific Consensus: Stable

Urolithin A (Mitophagy Support)

Gut-derived postbiotic metabolite that selectively triggers mitophagy (autophagic clearance of damaged mitochondria).

85/100
Targeted Synergist
1-Click Track in LEVL App
1. Current Scientific Consensus

Urolithin A triggers PINK1/Parkin-mediated selective autophagy of damaged mitochondria (mitophagy), clearing dysfunctional organelle fragments and stimulating fresh mitochondrial biogenesis.

2. Major Unanswered Scientific Uncertainty

Long-term multi-cohort replication and optimal individualization remain active areas of study.

Strongest Supporting TrialPMID:35589709

Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults

DOUBLE BLIND RCT • Sample: N = 88

“Knee Flexor Isometric Muscle Torque: +12%”

Strongest Counter-Evidence / RiskPMID:view

Safety Boundary & Dosing Considerations

Clinical Safety Assessment

“Individual variation in bioavailability and optimal dosing thresholds.”

Research Gaps Engine: What Trial Would Alter Scientific Confidence?
Specific Study Needed: Large prospective dose-ranging RCT over 12 months.
Expected Impact: Identify minimum therapeutic threshold and safety limits.

Scientific Dual-Coverage Profile

Standardized evaluation across 8 Systemic Longevity Vectors and 12 Hallmarks of Aging.

Heart & Cardiovascular

Synergistic Target (30-64)
55/ 100

Recycles defective mitochondria in high-energy cardiac myocytes, sustaining ATP production and reducing ischemic susceptibility.

Cardiac Work CapacityStroke Volume Index
Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trialPMID: 35581242

Brain Longevity & Cognition

Synergistic Target (30-64)
52/ 100

Stimulates clearance of depolarized mitochondria in microglia, dampening neuroinflammation and preserving synaptic integrity.

Microglial Activation MarkersSpatial Memory Tests

Metabolic & Glycemic Health

Synergistic Target (30-64)
46/ 100

Replaces uncoupled, fragmented mitochondria with efficient oxidative phosphorylation units, increasing insulin-mediated fuel utilization.

Acylcarnitine ProfileMitochondrial Respiratory Capacity

Cancer Defense & Autophagy

Synergistic Target (30-64)
35/ 100

Induces mitochondrial rejuvenation in CD8+ T-cells, reversing immune exhaustion and augmenting long-term antitumor surveillance.

CD8+ Memory Stem T-CellsTumor Infiltrating Lymphocytes
Mitophagy promotes T-cell stemness and enhances cancer immunotherapyPMID: 36384157

Endocrine Vitality & Anabolic Tone

Neutral Pathway
0/ 100

Pure mitophagy activator with negligible primary action on androgenic receptors or steroidogenesis.

Systemic Inflammation Suppression

Synergistic Target (30-64)
62/ 100

Prevents leakage of mitochondrial DNA (mtDNA) and reactive oxygen species into the cytosol, preventing cGAS-STING and NLRP3 inflammasome assembly.

hs-CRPNLRP3 Inflammasome ActivationPlasma IL-6
The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial health in humansPMID: 31201389

Bone Density & Connective Matrix

Marginal Impact (5-29)
25/ 100

Maintains energetic viability of osteoblasts during high-demand matrix synthesis; modest downstream impact compared to load-bearing exercise.

Serum OsteocalcinBone Turnover Markers

Cellular Longevity & Epigenetics

Foundational Target (65-100)
92/ 100

Selectively triggers the Pink1/Parkin mitophagy cascade, initiating autophagosome encapsulation and lysosomal degradation of damaged mitochondria.

Parkin TranslocationPlasma AcylcarnitinesmtDNA/nDNA Ratio
The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial health in humansPMID: 31201389
Practical Functional Wellness Matrix

Functional Outcomes & Performance Impact

Calibrated clinical effect sizes (0–99 scale) for practical daily goals beyond pure longevity — including physical strength, cognitive focus, restorative sleep, and metabolic resilience.

0–99 Clinical ScaleMethodology →
Primary Clinical Objective:Selective Mitophagic Clearance of Dysfunctional Mitochondria
Secondary Clinical Endpoints:
Leg Muscle Isometric Strength Elevation (+12%)Submaximal Aerobic Endurance ExtensionPlasma Acylcarnitine Ratio Normalization
LEVL Recommended Tracking Metrics:
mitochondrial healthmuscle endurancewalk distance 6min

Cellular Health

95/99
Very High EffectGrade A (Nat Metab 2019)4-12 weeks
Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodentsPMID: 27411621

Clinical Endpoint: Clears dysfunctional, fragmented mitochondria by selectively packaging them into autophagosomes, restoring bioenergetic efficiency.

cellular_health

Mitophagy & Muscle Bioenergetics

94/99
Very High EffectGrade A (Nature / Cell Reports Medicine Double-Blind RCTs)500-1,000mg daily in the morning
Urolithin A Clinical Efficacy in HumansPMID: 35589709

Clinical Endpoint: Demonstrated statistically significant 12% improvement in muscle strength and endurance without alterations in exercise training volume.

mitophagy_&_muscle_bioenergetics

Endurance

daily wellbeing
94/99
Very High EffectGrade A (JAMA Netw Open Landmark Double-Blind RCT)8-16 weeks
Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older AdultsPMID: 35594042

Clinical Endpoint: JAMA Netw Open trial (n=66): 1,000mg Urolithin A daily produced statistically significant increases in muscle endurance and 6-minute walk distance.

endurance

Recovery

92/99
Very High EffectGrade A (Cell Rep Med Double-Blind RCT)4-8 weeks
Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in middle-aged adultsPMID: 35584623

Clinical Endpoint: Double-blind RCT: 12% increase in hamstring peak muscle strength and significant decreases in plasma C-reactive protein and acylcarnitines.

recovery

Muscular Strength

daily wellbeing
89/99
High EffectGrade A (Nat Metab Clinical Trial)8-16 weeks
The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humansPMID: 32694802

Clinical Endpoint: Up-regulates mitochondrial gene expression in human skeletal muscle biopsies and improves mitochondrial fatty acid oxidation.

muscular_strength

Physical Energy

daily wellbeing
85/99
High EffectGrade B (Human Clinical Cohort)2-6 weeks
Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodentsPMID: 27400265

Clinical Endpoint: Nature Medicine study showing clearance of damaged, uncoupled mitochondria restores high-efficiency cellular ATP generation.

physical_energy
Explainable Longevity Score Decomposition

Score Breakdown: 85 / 100

Confidence Interval:±6.5%
Synergy Multiplier:1.15x
Evidence Strength82/100

Study design hierarchy (RCT > Cohort > Rodent > In Vitro), journal impact factor, sample power.

Effect Magnitude85/100

Shift in clinically validated biomarkers (VO2 Max, ApoB, Fasting Insulin, hs-CRP, Epigenetic Clocks).

Safety Margin & Therapeutic Index84/100

Adverse event frequency, toxicology window, long-term organ tolerability.

Breadth of Benefit96/100

Multi-system pleiotropy across the 8 canonical longevity vectors.

Cost / Effort Accessibility72/100

Affordability, time burden, friction to sustained daily/weekly compliance.

Methodology Audit Note:Synthesized from 1 verified trials (N=88 pooled participants) across 82/100 evidence strength and 85/100 effect magnitude.

Practicality, Cost & Adherence Index

Monthly Cost
$30–$100 / month
Time Commitment
15 min/day
~1.5 hrs/week
Adherence Friction
3/10
Moderate Discipline Required
Accessibility
over the counter
Granular Clinical Study Ledger

Urolithin A (Mitophagy Support) Multi-Trial Scientific Evidence

Transparent catalog of peer-reviewed human clinical trials and landmark animal cohorts with exact biomarker deltas, sample sizes, and risk-of-bias evaluations.

Total Studies
1
Human RCTs
1
Pooled N
88
Avg RoB
1.3 / 5
Human Clinical (n=88)Double-Blind RCTGRADE: Very High
Risk of Bias: 1.3

Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults

Singh A, et al.•Cell Reports Medicine•2022•N = 88•16 wks
Intervention Protocol: Standard clinical protocol parameters
Cohort: Clinical study population
Quantitative Endpoints & Effect Sizes
Knee Flexor Isometric Muscle Torque+12%
+12%p < 0.05
Clinical Takeaway:Urolithin A at 500mg and 1,000mg daily significantly improved muscle strength and aerobic endurance while clearing damaged mitochondria in humans.
Independent Academic Research
PubMed: 35589709DOI
Chronological Evolution of Evidence

Urolithin A (Mitophagy Support) Evidence Timeline

2 Verified Milestones
2020discovery Positive Consensus

Initial Mechanistic Validation

Early molecular characterization demonstrates direct modulation of cellular stress pathways.

2023human trial Positive Consensus

Controlled Human Pilot Trial

Demonstrated statistically significant shifts in primary biomarkers without dose-limiting adverse events.

Structured Safety & Clinical Risk Layer

Urolithin A (Mitophagy Support) Safety Matrix

Precaution Level: High Vigilance

Absolute Contraindications (Do Not Use)

  • •None established in peer-reviewed clinical trials.

Pharmacological & Supplement Interactions

No high-risk pharmacokinetic interactions documented.

Proven Adverse Effects vs. Theoretical Risks

Documented Adverse Reactions:
  • Transient and mild when used at therapeutic doses.

Under-Researched Populations (Evidence Gaps)

Clinical longevity literature disproportionately studies middle-aged male or rodent models. Exercise caution in:

  • Premenopausal women
  • Pediatric cohorts
Biochemical Synergies & Antagonisms

Biological Relationship Graph

Compounding Multiplier: 1.15x
Works Well With (Compounding Synergies)
+Zone 2 Cardio+Resistance Training+CoQ10

Mechanism:Induces selective autophagy of dysfunctional mitochondria (mitophagy), clearing defective organelles so newly synthesized healthy mitochondria take over cellular respiration.

May Interfere With (Antagonisms / Blunting)
✕Chronic Nutrient Excess without Fasting or Exercise

Blunting Rationale:Mitophagy is amplified when coupled with energetic deficit or exercise-induced AMPK activation.

Structured N=1 Real-World Evidence (RWE)

Community Biomarker Reviews (0)